NCBP2

Nuclear cap-binding protein subunit 2 · P52298 · NCBP2 on Sugi Atlas →

0 patent compounds predicted against NCBP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NCBP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids PHASE1COMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2 nanUNKNOWN
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) nanCOMPLETED
Tecfidera Diffusion Tensor Imaging nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA) nanRECRUITING
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
MD2, Cystatin C and DNA Methylation Tags as Serum Biomarkers for POCD. nanUNKNOWN
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Cataract Surgery to Obtain Human Lens Material for the Study of Nuclear Cataracts nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs nanUNKNOWN
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain nanCOMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Exploring the Genetics of Neuropathic Pain nanRECRUITING
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) nanUNKNOWN
Genetic Determinants of Exercise-Induced Muscle Damage (POLYGENDOMUS) nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Epigenetics, DNA Methylation Patterns and Periodontal Disease nanCOMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NCBP2 binder may also engage these)

ProteinNameSimilarity
Q3ZBJ1 1.000 Q3ZBJ1 →
B1WC40 1.000 B1WC40 →
Q9CQ49 1.000 Q9CQ49 →
C1BY64 0.999 C1BY64 →
P52299 0.998 P52299 →
Q8JGR6 0.997 Q8JGR6 →
B4JUT1 0.997 B4JUT1 →
B4PL68 0.997 B4PL68 →
C0H859 0.997 C0H859 →
B3P0D7 0.996 B3P0D7 →
B4NB54 0.996 B4NB54 →
B4LZ88 0.996 B4LZ88 →
B3LYP1 0.996 B3LYP1 →
A2SW84 0.995 A2SW84 →
B4KCD5 0.994 B4KCD5 →
Q9P383 0.994 Q9P383 →
Q293V6 0.994 Q293V6 →
B5G279 0.993 B5G279 →
Q6DES0 0.993 Q6DES0 →
Q177H0 0.993 Q177H0 →
B7P877 0.993 B7P877 →
B0W939 0.993 B0W939 →
B4M205 0.992 B4M205 →
Q08920 0.992 Q08920 →
B4QV17 0.992 B4QV17 →
B4GLK8 0.992 B4GLK8 →
B4IBA4 0.992 B4IBA4 →
Q1HE01 0.991 Q1HE01 →
Q5ZKR5 0.991 Q5ZKR5 →
Q93594 0.990 Q93594 →